Beam Therapeutics Q1 revenues beat estimates as its gene-editing pipeline advanced, with key updates across the SCD, AATD and ...

After two years of tweaks and slow-scaling pilots, Abridge is bringing AI to the nurses' stations.

Tissue Dynamics Ltd. and Galmed Pharmaceuticals Ltd. ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver disease and GI oncological therapeutics, today announced a ...

AUVELITY is a first-in-class treatment, which targets the NMDA and sigma-1 receptors, approved for agitation associated with dementia due to ...

Agios Pharmaceuticals AGIO reported a loss of $1.69 per share for the first quarter of 2026, narrower than the Zacks ...

Recent BEAM-302 Topline Data in Alpha-1 Antitrypsin Deficiency (AATD) Demonstrate Strong Single-dose Safety and Efficacy Profile, with 60 mg ...

AUVELITY is a first-in-class treatment, which targets the NMDA and sigma-1 receptors, approved for agitation associated with dementia due to Alzheimer's disease The safety and tolerability profile of ...

CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the first quarter ended March 31, 2026. “The first quarter reflected continued execution across CRISPR Therapeutics’ platform,” ...

CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the first quarter ended March 31, 2026. "The first quarter reflected ...

US FDA approves Axsome Therapeutics’ Auvelity to treat agitation associated with dementia due to Alzheimer’s disease: New York Axsome Ther ...

What if one of the biggest opportunities in critical minerals isn’t lithium, copper, or uranium — but a metal most investors still barely talk about? Scandium is used to strengthen aluminum alloys, ...

Forbes contributors publish independent expert analyses and insights. Transformative Travel: I look at how travel can change lives. This article is more than 3 years old. How to make money online: ...